Prosecution Insights
Last updated: November 04, 2026

Abcuro Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Abcuro Inc. is currently processing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is under the review of examiner HAUK TEODORO, PRICILA NMN, who is the busiest examiner for the portfolio with 1 pending office action. Current data indicates that prosecution is limited to 1 distinct examiner and 1 distinct art unit.

The portfolio's structure is highly concentrated, as all activity is confined to a single art unit and 1 distinct examiner. Because HAUK TEODORO, PRICILA NMN is responsible for this pending office action, the company's immediate success in Biotechnology & Pharmaceuticals depends on this specific interaction. This narrow focus suggests a targeted intellectual property strategy.

The presence of only 1 pending office action allows for a simplified management process. With no other pending matters or distinct art units to monitor, the company can dedicate its resources to this single application. This streamlined approach is typical for portfolios in a focused stage of development, where 1 distinct examiner handles the entire workload.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HAUK TEODORO, PRICILA NMN 1 50.0% +0.0%

Top Art Units

Art UnitApps
1645 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18291013 KILLER CELL LECTIN-LIKE RECEPTOR SUBFAMILY G MEMBER 1 (KLRG1) DEPLETING ANTIBODIES HAUK TEODORO, PRICILA NMN 1645 §102DP Non-Final OA — Pending Jan 22, 2024

Managing Abcuro Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Abcuro Inc. have?

Abcuro Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Abcuro Inc. applications?

Pricila Nmn Hauk Teodoro has the most, with 1 of Abcuro Inc.'s pending office actions.

What technology area are Abcuro Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month